Literature DB >> 10912837

Costs induced by hip fractures: a prospective controlled study in Belgium. Belgian Hip Fracture Study Group.

P Autier1, P Haentjens, J Bentin, J M Baillon, A R Grivegnée, M C Closon, S Boonen.   

Abstract

The economic burden of hip fractures is thought to be important, but the excess medical costs they induce remain largely unknown. We assessed the direct medical costs induced by hip fractures during and after hospitalization. Hospital costs of 170 consecutive Belgian women with hip fracture were gathered. During the year following discharge, all medical costs were collected for the 159 hip fracture women who survived the acute hospitalization stay. A similar collection of data was performed on a comparison group of 159 age-and residence-matched women without a history of hip fracture. The mean cost of the acute hospital stay was 8,667 Belgian francs and the mean 1-year hip-fracture-related extra costs after hospitalization was 6,636 Belgian francs. During the year following the acute hospital stay, 19% of the hip fracture women and 4% of the comparison women were newly admitted to nursing homes (p<0.001). Although health care costs increased with age, hip-fracture-related extra costs after hospitalization seemed similar in those below or above 81 years old. These extra costs amounted to 7,710 Belgian francs in women not living in nursing homes at the time of fracture, and to 3,479 Belgian francs in women who lived in nursing homes. Health or mental status before hip fracture seemed not to affect extra costs. Taking into account the higher mortality of women with hip fracture, the extra costs during the acute hospital stay and during the 1-year follow-up amounted to a mean 15,151 Belgian francs. In conclusion, both acute hospital stays and subsequent medical care contribute significantly to medical costs induced by hip fractures.

Entities:  

Mesh:

Year:  2000        PMID: 10912837     DOI: 10.1007/s001980070102

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  39 in total

Review 1.  Fracture Liaison Services in the United Kingdom.

Authors:  Paul J Mitchell
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

Review 2.  Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club.

Authors:  Steven Boonen; Jean-Jacques Body; Yves Boutsen; Jean-Pierre Devogelaer; Stefan Goemaere; Jean-Marc Kaufman; Serge Rozenberg; Jean-Yves Reginster
Journal:  Osteoporos Int       Date:  2005-01-26       Impact factor: 4.507

3.  Validation of the Malay version of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO-41) in Malaysia.

Authors:  Thiagarajan Nagammai; Mohamed Mohazmi; Su May Liew; Karuthan Chinna; Pauline Siew Mei Lai
Journal:  Qual Life Res       Date:  2015-02-04       Impact factor: 4.147

4.  Epidemiology of hip fractures in northwestern Italy: a multicentric regional study on incidence of hip fractures and their outcome at 3-year follow-up.

Authors:  Federico Dettoni; Alberto Peveraro; Angelo Dettoni; Roberto Rossi; Filippo Castoldi; Ali Zareh; Fabrizio Amberti; Alessio Giai Via; Alessio Giai Via; Davide Bonasia
Journal:  Musculoskelet Surg       Date:  2011-07-17

5.  Cutaneous side effects of antiosteoporosis treatments.

Authors:  Philippe Musette; Jean-Marc Kaufman; René Rizzoli; Patrice Cacoub; Maria Louisa Brandi; Jean-Yves Reginster
Journal:  Ther Adv Musculoskelet Dis       Date:  2011-02       Impact factor: 5.346

6.  Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm.

Authors:  K Kim; A Svedbom; X Luo; S Sutradhar; J A Kanis
Journal:  Osteoporos Int       Date:  2013-10-10       Impact factor: 4.507

7.  Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club.

Authors:  J-J Body; P Bergmann; S Boonen; Y Boutsen; J-P Devogelaer; S Goemaere; J-M Kaufman; S Rozenberg; J-Y Reginster
Journal:  Osteoporos Int       Date:  2010-05-18       Impact factor: 4.507

8.  Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women.

Authors:  M Hiligsmann; O Bruyère; J-Y Reginster
Journal:  Osteoporos Int       Date:  2009-04-07       Impact factor: 4.507

9.  Haemoglobin levels are associated with bone mineral density in the elderly: a population-based study.

Authors:  Alice Laudisio; Emanuele Marzetti; Francesco Pagano; Roberto Bernabei; Giuseppe Zuccalà
Journal:  Clin Rheumatol       Date:  2008-09-03       Impact factor: 2.980

10.  Denosumab: an investigational drug for the management of postmenopausal osteoporosis.

Authors:  E Michael Lewiecki
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.